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Many bacterial pathogens secrete virulence (effector) proteins
that interfere with immune signaling in their host. SpvD is a Sal-
monella enterica effector protein thatwe previously demonstrated
to negatively regulate the NF-B signaling pathway and promote
virulence of S. enterica serovar Typhimurium in mice. To shed
light on the mechanistic basis for these observations, we deter-
mined the crystal structureof SpvDand showthat it adopts apapa-
in-like fold with a characteristic cysteine-histidine-aspartate cata-
lytic triad comprising Cys-73, His-162, and Asp-182. SpvD
possessed an in vitro deconjugative activity on aminoluciferin-
linked peptide and protein substrates in vitro. A C73A mutation
abolished SpvD activity, demonstrating that an intact catalytic
triad is required for its function. Taken together, these results
strongly suggest that SpvD is a cysteine protease. The amino acid
sequence of SpvD is highly conserved across different S. enterica
serovars, but residue161, locatedclose to the catalytic triad, is vari-
able,withserovarTyphimuriumSpvDhavinganarginineandsero-
var Enteritidis a glycine at this position. This variation affected
hydrolytic activity of the enzymeon artificial substrates and canbe
explained by substrate accessibility to the active site. Interestingly,
the SpvDG161 variant more potently inhibited NF-B-mediated
immune responses in cells in vitro and increased virulence of sero-
varTyphimuriuminmice. In summary, our results explain thebio-
chemical basis for the effect of virulence protein SpvDanddemon-
strate that a single amino acid polymorphism can affect the overall
virulence of a bacterial pathogen in its host.
Salmonella enterica serovars Typhimurium and Enteritidis
are broad host range intracellular bacterial pathogens causing
gastrointestinal disease in humans and a typhoid-like systemic
infection in certain mouse strains. Their virulence depends on
the activity of two type III secretion systems (T3SSs),5 encoded
by the pathogenicity islands Salmonella pathogenicity island 1
(SPI-1) and SPI-2 that enable translocation of effector proteins
into host cells. Themajority of effector proteins are encoded on
the bacterial chromosome, but some are present on the pSLT
virulence plasmid (1). An important virulence determinant of
the pSLT plasmid is the Salmonella plasmid virulence locus
(spv) (2–5), which comprises the spvABCD operon and its
upstream regulator spvR (6). SpvB is an ADP ribosyl transferase
that depolymerizes F-actin (7), and SpvC is a phosphothreonine
lyase that inhibits mitogen-activated protein kinase signaling
(8, 9). Mass spectrometry analysis of proteins secreted by Sal-
monella identified SpvD as an effector of both SPI-1 and SPI-2
T3SSs (10). Previously, we confirmed that SpvD contributes to
virulence during systemic infection ofmice (10, 11) and showed
it inhibits the NF-B signaling pathway and secretion of proin-
flammatory cytokines from infected macrophages (11). In this
workwe determined the structure of SpvD and showed that it is
a hydrolase with a papain-like fold and a catalytic triad com-
posed of Cys-73, His-162, and Asp-182. Although SpvD is
highly conserved among different serovars of S. enterica, sero-
vars Typhimurium and Enteritidis differ in containing an argi-
nine or glycine, respectively, at residue 161 near the active site.
We show that this polymorphism affects hydrolytic activity,
degree of inhibition of the NF-B pathway, and remarkably,
bacterial virulence in mice.
Results
SpvD Adopts a Papain-like Fold—To gain insight into the
function of SpvD, we attempted to determine its crystal struc-
ture. After unsuccessful crystallization of wild-type SpvD, we
obtained crystals of SpvD in which its predicted surface cys-
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teines were mutated (SpvDC37S/C122S/C160S/C170S, hereafter
referred to as SpvD4CS), and these diffracted to 1.5 Å resolution
(Table 1). Subsequent structure determination revealed that
SpvD adopts an  fold with a total of 7 -helices, 6
-strands, and a short stretch of 310 helix (Fig. 1, A and B). Its
central core is composed of a -sheet formed by four antipar-
allel -strands (3–6) surrounded by five -helices (3–7).
Additionally, there is a smaller -sheet (1–2) surrounded by
-helices 1–5 (Fig. 1, A and B). Close inspection of a shallow
groove on the protein surface betweenhelices4/5, strand4,
and the 5-7 loop revealed a potential hydrolase active site
including a catalytic triad of cysteine (Cys-73), histidine (His-
162), and aspartic acid (Asp-182) (Fig. 1, A and C). A structure
similarity search performed with the DALI software (12)
revealed similarities to four other secreted effector proteins:
OspI (a T3SS deamidase of the Gram-negative bacterial patho-
gen Shigella flexneri) (13, 14), SseI (a S. typhimurium SPI-2
T3SS effector protein of unknown enzymatic activity) (15),
AvrPphB (a T3SS cysteine protease of a bacterial plant patho-
gen Pseudomonas syringae) (16), and SspB (a cysteine protease
secreted by Staphylococcus aureus) (17) as well as other papain
and papain-like cysteine proteases. These all have a character-
istic central antiparallel -sheet and catalytic cysteine-contain-
ing -helix (Fig. 2). Superimposition of these structures
revealed that the orientation of the catalytic triads in papain,
OspI, AvrPphB, staphopain B, SseI, UCH-L3, UCH-6, and
cathepsin B proteins are almost identical to that of SpvD (Fig.
1D) (14–20).
A Naturally Occurring SpvD Variant with Enhanced Enzy-
matic Activity—The amino acid sequence of SpvD varies
among serovars of S. enterica (21). We carried out a protein
BLAST search using the amino acid sequence of S. typhimu-
rium 14028 SpvD. This confirmed previously described poly-
morphisms and found sequences homologous to SpvD in other
bacterial species such as Pseudomonas psychrophila and Provi-
dencia burhodogranariea (supplemental Fig. S1). Within the
broad host range serovars of S. enterica, Enteritidis and
Typhimurium, there are only two positions that consistently
vary in amino acid composition (154 and 161) (Fig. 3A and
supplemental Fig. S1). Within Typhimurium serovars, an ala-
nine is encoded at position 154, and an arginine is encoded at
position 161. In contrast, all Enteritidis serovars sequenced to
date have either alanine or valine at position 154 and glycine at
position 161 (Fig. 3A). Both residues are in close proximity to
the catalytic triad, and their side chains contribute to the struc-
ture of the active site groove (Fig. 3B, blue and green sticks).
Positions 154 and 161 of SpvD homologues in species other
than Salmonella aremainly occupied by small hydrophobic res-
idues (leucine and isoleucine at 154 and glycine and alanine at
161; supplemental Fig. S1). Within Salmonella, the Gly-161
polymorphism appears to be unique to Enteritidis, Abortus-
equi, and Bovismorbificans serovars as all others (Typhimu-
rium, Dublin, Paratyphi C, Gallinarum, Pullorum, and Chol-
eraesuis) contain arginine at this position (supplemental Fig.
S1).Weused a variety of assays to determine the potential enzy-
matic activity of SpvD. Structural similarity to ubiquitin hydro-
lases suggested that SpvD could be a deubiquitinase. In a screen
that utilizes a C-terminal peptide of ubiquitin (RLRGG) fused
to aminoluciferin for detection of ubiquitin and ubiquitin-like
cysteine proteases (DUB-GloTM protease assay; Promega), we
found that SpvD, like the known Salmonella deubiquitinase
(DUB) SseL (22, 23), produced a stable and specific lumines-
cence signal indicative of substrate hydrolysis. Consistent with
the crystal structure, SpvD hydrolytic activity was dependent
on cysteine 73 of its putative catalytic triad (Fig. 3C). Interest-
ingly, conversion of the SpvD sequence to that of the Enteritidis
TABLE 1
Data collection and refinement statistics
r.m.s.d., root mean square deviation; SIRAS, single isomorphous replacement with anomalous scattering (data set collected from crystals soaked in KAuCl4).
SpvD4CS/A154/R161 SpvD4CS/A154/G161/C73A SpvD (Au SIRAS)
Data collection
Wavelength (Å) 0.97625 0.97949 0.92000
Space group P21 P21 P21
Cell dimensions
a, b, c (Å) 43.7, 51.81, 47.27 44, 51.97, 47.22 43.84, 52.11, 47.38
, ,  (°) 90, 107.41, 90 90, 107.7, 90 90, 107.84, 90
Resolution range (Å) 51.81–1.48 (1.56–1.48)a 51.97–1.60 (1.69–1.60) 41.73–2.25 (2.31–2.25)
Reflections, total 195,684 (21,204) 156,479 (23,249)
Reflections, unique 33,404 (4614) 26,737 (3,893)
I/I 12.1 (2.1) 10.4 (1.9) 18.1 (3.8)
Rmerge 0.076 (0.869) 0.104 (1.018) 0.108 (0.531)
Completeness (%) 99.1 (94.1) 99.4 (99.2) 100 (60.8)b
Multiplicity 5.9 (4.6) 5.9 (6.0) 6.4 (4.2)b
Refinement
Rfactor/Rfree (%) 16.96/20.15 16.32/19.73
No. of atoms
Protein 1,556 1,713
Ligand/ion 1 18
Water 182 205
Bfactors
Protein 22.07 19.96
Ligand/ion 17.18 28.19
Water 30.76 30.61
r.m.s.d. bond length (Å) 0.0151 0.0164
r.m.s.d. bond angle (°) 1.573 1.410
Ramachandran favored/outliers (%) 98.9/0 98.1/0.5
a Values in parentheses correspond to the highest resolution shell.
b Completeness and multiplicity values given for anomalous data.
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strains increased the activity observed in the DUB-GloTM pro-
tease assay (Fig. 3, C and D). At the highest concentration
tested, the most active variant, SpvDA154/G161, produced over
10 times more luminescence signal than SpvDA154/R161, 5 h
after the start of the assay (Fig. 3, C andD). In this assay, prote-
ase and luciferase activities normally reach a steady state so that
a maximal signal is reached after 30 min and maintained for
several hours. In contrast to SseL and SpvDA154/R161, the lumi-
nescence signal produced by the SpvDA154/G161 and SpvDV154/G161
variants did not stabilize after 30min but continued to increase
up to 5 h (Fig. 3D). SpvDV154/G161 had an intermediate activity
in the DUB-GloTM assay, in between that of SpvDA154/R161 and
SpvDA154/G161 (Fig. 3C and D). Due to the more pronounced
effect of the variation at position 161, we focused further stud-
ies on this polymorphism, maintaining alanine at position 154.
To explain why the Gly-161 polymorphism leads to greater
activity, we crystallized an inactive (C73A) form of the variant
in the presence of RLRGG-AML substrate. Although density
FIGURE1.SpvDadoptedapapain-like foldwithCys-73,His-162,andAsp-182catalytic triad.A, crystal structureofS. typhimuriumSpvD4CS colored starting
from N terminus (blue) and ending at C terminus (red). Secondary structure elements and catalytic triad (sticks) are labeled in black. Cys-73/His-162/Asp-182
catalytic triad is shown in sticks. The imagewasgeneratedusingPyMOL software.B, secondary structure elementsmappedaccording to their respective amino
acid sequence and colored as inA. In the sequence, the catalytic triad residues are colored in red. Surface cysteinesmutated to serines are underlined.C, walleye
stereo view of the 2Fo  Fc electron density map of the active site region of the SpvD structure. D, superimposition of catalytic triad components of SpvD,
OspIC62A (PDB code 3W31), papain (PDB code 1PPN), AvrPphB (PDB code 1UKF), staphopain B (PDB code 1Y4H), SseI (PDB code 4G29), UCH-6 (PDB code 1VJV),
UCH-L3 (PDB code 1XD3), and cathepsin B (PDB code3AI8).
FIGURE 2. SpvD structure shared papain-like fold features. Schematic
representation of SpvDA154/R161, OspIC62A (PDB code 3W31), papain (PDB
code 1PPN), AvrPphB (PDB code 1UKF), staphopain B (PDB code 1Y4H),
SseI (PDB code 4G29), UCH-L3 (PDB code 1XD3), and cathepsin B (PDB
code 3AI8) is shown. The central -helix containing the catalytic cysteine
is colored in purple, and the main anti-parallel -sheet is colored in
green. Structures were oriented according to their superimposed catalytic
triads.
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for the RLRGG-AML substrate was not observed, we were able
to build additional loops (two of them near the active site) that
were disordered in the previously obtained SpvD4CS/R161 struc-
ture (supplemental Fig. S2). To map a potential ligand binding
site on SpvD, we superimposed the catalytic triad with that of
the UCH-L3 ubiquitin hydrolase crystallized in complex with
ubiquitin (Fig. 3E). The position of the superimposed five
C-terminal amino acids of ubiquitin (RLRGG) is unobstructed in
the SpvD4CS/G161/C73A variant (Fig. 3E, right), whereas in
SpvD4CS/R161, binding would be impeded by the side chain of
Arg-161, which restricts access to the active site (Fig. 3E, left).
Therefore, the Arg-161 side chain could have an inhibitory
steric or regulatory role in the activity of SpvD. These results
demonstrate that SpvD is a hydrolytic enzyme with a catalytic
triad that is characteristic of papain-like proteases. As theDUB-
GloTM protease assay detects ubiquitin and ubiquitin-like pro-
teases, we then assayed SpvD variants using full-length ubiqui-
tin-AML as a substrate. As expected, the positive control SseL
was active at all concentrations tested (1 M, 5 M, and 25 M;
Fig. 4A). Surprisingly, the only SpvD variant that produced a
specific, Cys-73-dependent signal was SpvDA154/R161 (Fig. 4, A
and B). The luminescent signal produced by SseL decreased
over time from an initial level of 100-fold above background,
indicating substrate depletion (Fig. 4B). In contrast SpvDA154/R161
FIGURE 3. SpvD had a deconjugative activity that varied between serovars. A, zoom on SpvD amino acid alignment highlighting the two main (154 and
161) polymorphisms occurring in Enteritidis and Typhimurium serovars. The red asterisk indicates the catalytic histidineHis-162. B, bothAla-154 (blue stick) and
Arg-161 (green stick) positions are situated in the vicinity of the CHD catalytic triad (red sticks). C, DUB-GloTM assay with three (1, 5, and 25 M) concentrations
of tested proteins. Results are expressed asmean S.E. of three independent experiments.Asterisks above the blue bars represent significant differenceswhen
compared with the buffer control (background) as measured by the Student’s t test. Comparison between SpvD variants at 25 M concentration was made
using one-way ANOVA statistical analysis with Bonferroni’s multiple comparison test. *, p 0.05; ***, p 0.005; NS, not significant. RLU, relative light units. D,
DUB-GloTM signal over time for the highest (25 M) concentration tested for SseL, SpvDA154/R161, SpvDA154/G161, and SpvDV154/G161. Signal intensities were
measured every 15 min for which  S.E. of three independent experiments are shown. E, modeling of the RLRGG peptide onto the surface of
SpvD4CS/A154/R161 (left) or SpvD4CS/A154/G161/C73A (right) using the C-terminal ubiquitin tail (RLRGG; cyan sticks) from theUCH-L3 ubiquitin hydrolase complexed
with ubiquitin (PDB code 1XD3). The catalytic triad region of SpvD is colored in red, Arg-161 is in green, and Gly-161 is in purple.
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FIGURE 4. SpvDR161 was active on a ubiquitin-AML substrate. A, a modification of the DUB-GloTM assay with RLRGG substrate replaced by a full-length
ubiquitin conjugated to aminoluciferin (Ub-AML). A representative assay result is shown. B, Ub-AML deconjugation assay over time measured for the highest
concentration (25 M) of the tested proteins. Signals were taken every 15 min. C, in vitro deubiquitination assay done with 5 M of either SseL (top) or
SpvDA154/R161 (bottom). Diubiquitin linkages were incubated with tested proteins for 0, 30, and 60 min followed by SDS-PAGE separation and Coomassie
staining. Detectable cleavage product in the form of a single ubiquitin band is indicated with an arrow. D, AMC deconjugation assay using ubiquitin-AMC
(yellow), ISG15-AMC (blue), NEDD8-AMC (orange), SUMO1-AMC (green), and SUMO2-AMC (red). Results are shown as mean fluorescence values with S.D. of
three technical repeats obtained 1 h after start of the experiment. Isopeptidase Twas used as a positive control for ubiquitin-AMC and ISG15-AMC. SENP2was
used as a control protease for SUMO1-AMC and SUMO2-AMC substrates, whereas NEDP1 was used in case of NEDD8-AMC.
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produced a level of luminescence that was 10-fold above
background and remained relatively constant over the course of
the assay. Interestingly, in this assay both SpvDV154/G161 and
SpvDA154/G161 displayed virtually no activity (Fig. 4, A and B).
To test if SpvDA154/R161 has linkage-specific deubiquitinat-
ing activity, diubiquitin molecules linked by seven different
lysine residues or methionine M1 were tested for cleavage.
SseL cleaved isopeptide molecules linked by Lys-11, Lys-48,
and Lys-63 (Fig. 4C, top), but SpvDA154/R161 had no detect-
able activity on any of the substrates (Fig. 4C, bottom). To
test if SpvDA154/R161 has activity against other ubiquitin-like
proteins, we used substrates comprising full-length ubiqui-
tin or four ubiquitin-like proteins (SUMO1, SUMO2,
NEDD8, and ISG15) C-terminally linked to 7-amino-4-meth-
ylcoumarin (AMC). SpvDA154/R161 had no detectable activity on
any of these substrates, whereas SseL produced a specific fluo-
rescent signal with ubiquitin-AMC as a substrate (Fig. 4D).
Inhibition of the NF-B Pathway by SpvD Is Dependent on
Cys-73 and Is Affected by Variation at Residue 161—We
showed previously that SpvD inhibits the NF-B signaling
pathway (11). To investigate the influence of the amino acid
side chain at position 161 and the requirement for the putative
catalytic cysteine (Cys-73) on the anti-inflammatory activity of
SpvD, HEK 293 cells were co-transfected with a reporter plas-
mid encoding luciferase under the control of an NF-B pro-
moter and a plasmid encoding either myc alone (pRK5 vector),
myc-SpvD variants with alanine at position 154, or GFP-tagged
positive control inhibitory proteins: Salmonella SseK3 (24) and
NF-B inhibitor  (IB) S32A/S36A mutant protein (25).
Luciferase activity was measured 16 h after stimulation with
TNF or phorbol 12-myristate 13-acetate (PMA) and normal-
ized to that of non-stimulated cells. TNF and PMA caused
25- and 20-fold increases in NF-B activation, respectively
(Fig. 5,A andB). Expression of tagged proteins was confirmed
by Western blotting (Fig. 5C). SseK3 is an effector that is
known to inhibit the NF-B pathway upon TNF stimula-
tion (14). In this assay it inhibited the reporter activity by
92% (Fig. 5A). After TNF stimulation, SpvDA154/R161 and
SpvDA154/G161 reduced NF-B fold activation by 36 and 41%,
respectively, and these effects were dependent on Cys-73 (Fig.
5A). There was no significant difference in the level of NF-B
inhibition between the Arg-161 and Gly-161 variants (Fig. 5A).
FIGURE 5. SpvD variants had differential NF-B inhibitory activities in PMA- but not in TNF-stimulated cells. NF-B luciferase assay from transfected
HEK293 cell line after 16 h stimulation with TNF (A) or PMA (B). Results are shown as -fold activation in relation to unstimulated cells. Values are expressed as
the mean S.E. of at least four independent experiments. Statistical significances were calculated using one-way ANOVA followed by Bonferroni’s multiple
comparison test against pRK5- or SpvDA154/R161-transfected cells (*, p  0.05; ***, p  0.005; NS, not significant). C, protein expression levels measured by
SDS-PAGEand immunoblottingwith anti-tubulin (top), anti-GFP (mid), andanti-myc (bottom) antibodies.Numbers on the sides correspond tomolecularweight
protein ladder in kDa.
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However, after stimulationwith PMA, both the positive control
protein IBS32A/S36A and SpvDA154/G161 inhibited the NF-B
pathway to a similar level (Fig. 5B), whereas SpvDA154/R161 had
amuch smaller effect. Therefore, the increased hydrolase activ-
ity of SpvDA154/G161 over SpvDA154/R161 in the DUB-GloTM
protease assay (Fig. 3C) correlates with an enhanced ability of
SpvDG161 to inhibit the NF-B inflammatory pathway in cells
stimulated with PMA.
Higher in Vitro Deconjugative and Anti-inflammatory Activ-
ities of Naturally Occurring SpvD Variant Correlate with Sal-
monella Virulence in Vivo—Salmonella strains lacking SpvD
were shown to be attenuated for growth in mice when com-
pared with the wild-type strain (10, 11). Having detected differ-
ent in vitro deconjugation and anti-inflammatory activities of
SpvD variants, we tested if the side chain at position 161 within
the SpvD active site influences Salmonella growth in vivo.
First, we confirmed bacterial translocation of C-terminal
double hemagglutinin (HA)-tagged SpvDA154/G161/C73A and
SpvDA154/R161/C73A into iBMDMs, showing that catalytic triad
mutations did not affect effector delivery (Fig. 6). Mice were
then inoculated by intraperitoneal injection with a mixture of
equivalent cfu of spvD mutant strain and chloramphenicol-
resistant spvDmutant strains harboring various pACYC184-
based complementation plasmids (Fig. 7). After 72 h of infec-
tion, bacteria were quantified after plating spleen homogenates
on LB agar medium and LB agar medium containing chloram-
phenicol to distinguish the strains. The competitive index (CI)
of spvD mutant and spvD mutant harboring an empty
pACYC184 plasmid (EV) was 0.34  0.04, showing that the
presence of pACYC184 incurred a fitness cost (Fig. 7). When
mixed with spvD strains carrying pACYC184 encoding either
SpvDA154/R161 or SpvDA154/G161, the CI of the spvD mutant
strain dropped from 0.34 to0.12 and0.39, respectively (Fig.
7). Interestingly, the spvD mutant was more efficiently out-
competed by the SpvDA154/G161 strain compared with the
SpvDA154/R161 strain, demonstrating that the more active
SpvDA154/G161 variant is more potent in complementing the
spvDmutation than SpvDA154/R161 (Fig. 7). Whenmixed with
spvD strains carrying plasmids encoding the C73A mutant
versions of SpvD, the spvD strain had CIs of 0.15  0.14 and
0.32  0.08 for SpvDA154/R161/C73A and SpvDA154/G161/C73A,
respectively) similar to the CI of the spvD strain mixed with
spvD strain harboring empty pACYC184 plasmid (Fig. 7).
Therefore, the ability of both SpvDA154/R161 and SpvDA154/G161
to complement the virulence defect was dependent on a func-
tional catalytic triad.
Discussion
In this work we have determined the structure of SpvD, a
S. typhimurium SPI-2 T3SS effector protein that inhibits the
FIGURE 6. Catalytically dead variants of SpvD were translocated from bacteria in iBMDMs. Cells were infected for 18 h with S. typhimurium spvD strain
carrying either an emptypWSK29plasmid (EV) or a pWSK29plasmid encodingC-terminally 2HA-taggedvariants of SpvDunder SPI-2 promoter. In the last 2 h
of infection, cellswere treatedwith10MMG-132proteasomal inhibitor. DNA, Salmonella, andHA-taggedSpvDwere stainedusingDAPI dye, CSA-1, andHA11
antibodies, respectively. Thewhite scale bar represents 5 M.
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NF-B signaling pathway (11). Structurally, SpvD can be clas-
sified as belonging to the CA clan of cysteine proteases that
contains papain and related proteases (MEROPS peptidase
database). A hallmark of this clan is a CHD (or CHN) catalytic
triad,which in the case of SpvD is composed ofCys-73,His-162,
and Asp-182. Using a DUB-GloTM assay, we showed that SpvD
is an enzyme with deconjugative activity. Taken together, the
results of our experiments strongly suggest that SpvD acts as a
protease. Due to the chemical nature of the DUB-GloTM sub-
strate (aminoluciferin fused to the C terminus of an RLRGG
peptide), the DUB-GloTM assay would potentially not only
detect deubiquitinases or ubiquitin-like proteases but any pro-
tease that recognizes and cleaves after a sequence similar toGG.
In all the assays tested (DUB-GloTM, NF-B inhibition, viru-
lence in mouse) the activity of SpvD was abolished by a C73A
mutation, demonstrating the necessity of an intact catalytic
triad for its function. Previously, we reported that SpvD specif-
ically interacts with exportin-2 to inhibit nuclear transport of
p65 (11). Although the results presented here provide addi-
tional evidence for a function of SpvD in inhibiting the NF-B
pathway, we have not been able to detect cleavage of endoge-
nous exportin-2 in HEK293 cells transiently expressing
SpvDA154/R161 or SpvDA154/G161 (data not shown). This sug-
gests that there might be another as yet unidentified substrate
that is modified by SpvD. Analysis of naturally occurring SpvD
polymorphisms revealed that position 161 is critical for the
deconjugative activity of SpvD in the DUB-GloTM assay. Mod-
eling of the RLRGGDUB-GloTM substrate onto the Arg-161 or
Gly-161 structures provides a rationale for this observation,
clearly showing that the side chain at position 161 forms part of
the active site groove and that an arginine side chain here
restricts access to the catalytic triad. Despite being less active in
the DUB-GloTM assay, SpvDA154/R161 was the most active SpvD
variant in the Ub-AML deconjugation assay. This suggested that
SpvDA154/R161might be a DUB or ubiquitin-like protease. How-
ever, we were unable to obtain evidence for this in subsequent
AMC deconjugation and in vitro deubiquitination assays.
When comparedwith theTyphimuriumSpvDA154/R161 variant,
SpvDwith a single polymorphism (Gly-161)wasmore potent in
(i) the DUB-GloTM protease assay, (ii) inhibition of the NF-B
luciferase assay in PMA-stimulated cells, and (iii) virulence in
mice. The observation that SpvDA154/G161 is more potent at
inhibitingNF-B signaling than SpvDA154/R161 in PMA-but not
TNF-stimulated HEK293 cells might help guide the identifi-
cation of its substrate. PMAmimics diacylglycerol in stimulat-
ing NF-B through activation of protein kinase C (26). There-
fore, our results suggest that the more active SpvD variant
targets a diacylglycerol-stimulated branch of NF-B pathway.
There are very few descriptions of single amino acid polymor-
phisms influencing the potency of bacterial effectors. A natu-
rally occurring polymorphism within S. typhimurium SseI at
position 103 was shown to affect binding to the cell migration
adaptor protein TRIP6 in a yeast two-hybrid assay and bacterial
dissemination in mice (27). However, the position of the SseI
polymorphism in relation to the catalytic site is unknown as
only partial SseI (amino acids 145–313) structure is currently
available (15). The SpvD polymorphism that we have investi-
gated here is in very close vicinity of the catalytic triad. Depend-
ing on the substrate used in vitro, the Arg-161 or Gly-161 var-
iant displayed greater potency. However, the Gly-161 variant
conferred stronger inhibition of a PMA-stimulated NF-B
reporter and greater virulence of Salmonella in mice. Regard-
less of the identity of the physiological substrate for hydrolytic
activity of SpvD, it is remarkable that a single amino acid sub-
stitution that alters hydrolytic potency can influence the com-
plex process of virulence in a host. The fact that the SpvDR161
variant is present in all Salmonella serovars except Enteritidis,
Bovismorbificans, and Abortus-equi is intriguing. It is possible
that SpvDR161 has gained a different substrate specificity that is
not related toNF-B signaling. Collectively, our results indicate
SpvD is a papain-like hydrolase that functions through a cys-
teine-mediated hydrolysis reaction to inhibit gene expression
from NF-B promoters. Furthermore, we demonstrate that a
natural SpvD polymorphism significantly affects virulence and
NF-B inhibition in PMA-stimulated cells, leading us to
hypothesize that the substrate hydrolyzed by SpvDG161 might
be part of a signaling pathway involving protein kinase C.
Experimental Procedures
Bacterial Strains and Plasmids—Bacterial strains and plas-
mids used in this study are listed in supplemental Table S1. The
Salmonella strains were grown in Luria Bertani (LB) medium at
37 °Cwith shaking and supplementedwith ampicillin (100g/ml)
or chloramphenicol (34g/ml) as appropriate. Complementation
plasmids (pACYC184orpWSK29)containingnon-taggedordou-
bleHA-tagged spvDwere obtained using restriction enzyme clon-
FIGURE 7. SpvDA154/G161 conferred increased virulence over
SpvDA154/R161. C57BL/6 mice were inoculated by intraperitoneal injection
with equal numbers (5 102 cfu of each of the two strains) of the indicated
bacteria. Bacteria were recovered from infected spleens 3 days post-inocula-
tion. CI values were calculated as described under “Experimental Proce-
dures.” The scatter plot displays values obtained for individual mice and the
mean are indicated (line). Statistical significances were calculated using one-
way ANOVA followed by Bonferroni’s multiple comparison test. **, p 0.01;
***, p 0.005.
SpvD Structure and Activity
25860 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 50•DECEMBER 9, 2016
 at U
niversity of Sussex Library on Septem
ber 21, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ing. Site-directed mutagenesis of SpvD was performed by inverse
PCR using pRK5-myc-SpvDA154/R161 vector as DNA template.
Protein Production—For crystallography,
SpvDC73S/C122S/C160S/C170SandSpvDC73S/C122S/C160S/C170S/C73A/G161
were expressed with a precision protease-cleavable N-terminal
His6 tag from pHiSH, a pET15b-derived vector (28) in PC2 cells
(29). Cultures were grown in Terrific Broth or LB to anA600 of 0.8
at 37 °C and inducedwith 0.5mM isopropyl 1-thio--D-galactopy-
ranoside for 16 h at 18 °C. Cells were lysed by sonication in 50mM
Tris/Cl, pH 7.5, 500 mM NaCl, 20 mM imidazole, 0.5 mM phenyl-
methylsulfonyl fluoride. After clarification by centrifugation, the
lysate was mixed with nickel-nitrilotriacetic acid resin for 1 h at
4 °C.Theresinwasextensivelywashedwith50mMTris/Cl, pH7.5,
500mMNaCl, and 20mM imidazole, and SpvDwas elutedwith 50
mMTris/Cl, pH7.5, 500mMNaCl, and500mMimidazole.TheHis
tagwas removed by the addition of 10mMdithiothreitol andHRV
3C protease at a ratio of 1 mg protease to 30 mg SpvD and over-
night incubation at 4 °C. The SpvD solution was loaded onto a
Superdex75 gel filtration column (GE Healthcare) pre-equili-
brated in 50mMTris/Cl, pH7.5, 150mMNaCl, and 10mM-mer-
captoethanol. For biochemical analyses, GST-SseL, SpvC-His6,
and SpvDA154/R161-His6 proteins were purified from previously
generated pGEX and pET22b vectors (9, 11, 22). Variants of SpvD
were made using site-directed mutagenesis, and their protein-
coding DNA sequences were ligated into pET22b using identical
restriction sites. Protein was expressed in Escherichia coli
BL21(DE3) cells thatweregrowntoanA600 of 0.8–1.0 at 37 °Cand
induced with 1 mM isopropyl 1-thio--D-galactopyranoside for
16–20 h at 20 °C. Depending on the protein fusion tag, proteins
were purified to apparent homogeneity using either nickel- or glu-
tathione-based affinity chromatography as described previously
(9, 22).
DUB-GloTM and Ub-AML Assays—Purified SpvC, SseL, and
SpvD proteins were each used in the DUB-GloTM assay at 1, 5,
and 25 M concentrations. The DUB-GloTM assay was per-
formed using the manufacturer’s instructions (Promega).
Briefly, 50 l of 2, 10, and 50 M of tested proteins diluted in
reaction buffer (50 mM HEPES, pH 7.4, 50 mM NaCl, 0.5 mM
EDTA, 10 mM DTT) was mixed with 50 l of RLRGG-AML
substrate containing luciferase reporter enzyme. Luciferase
activity was measured at 22 °C every 15 min up to 5 h with an
Infinite M200Pro plate reader (Tecan). In a modification of the
assay, 40 M RLRGG-AML was replaced with 1 M Ub-AML,
whereas the remaining buffer composition and luciferase
enzyme remained unchanged.
AMC Deconjugation Assay—SseL, SpvC, SpvDA154/R161, and
relevant control proteins were incubated with 1 M concentra-
tions of ubiquitin-, SUMO1-, SUMO2-, ISG15-, and NEDD8-
AMC (Boston Biochem) in 50 mM HEPES, pH 8.0, and 1 mM
DTT. Liberation of AMC at 22 °C was measured after 1 h of
incubation using Infinite M200Pro plate reader (Tecan; excita-
tion/emission wavelengths 380/460 nm).
In Vitro Deubiquitination Assay—A panel of M1 linear Lys-
6-, Lys-11-, Lys-27-, Lys-29-, Lys-33-, Lys-48-, and Lys-63-
linked diubiquitin chains was acquired from UbiQ. The reac-
tion mixture contained 50 mMHEPES, pH 7.5, 100 mMNaCl, 1
mM EDTA, 5 mM DTT, and 5 M diubiquitin chains. Diubiqui-
tin hydrolysis reactionswere performed at 37 °C by adding 5M
concentrations of either SseL (positive control) or SpvD. The
assay was started by mixing the tested protein and diubiquitin
solutions, and 10-l aliquots were taken at the indicated time
points. The reaction was resolved on 4–12% SDS-PAGE gradi-
ent gels run in MES buffer (Invitrogen) and stained with Coo-
massie Brilliant Blue R-250 (Bio-Rad).
Antibodies—Immunofluorescence analysis was done using
goat anti-Salmonella (CSA-1, Kirkegaard and Perry Laborato-
ries) and mouse anti-HA (HA11, Covance) antibodies. Immu-
noblotting of tagged proteins was performed using 9e10 (Roche
Applied Science) and GFP (Life Technologies) antibodies.
Tubulin was probed with E7 antibody (Developmental Studies
Hybridoma Bank).
Cell Culture—HEK293 (human embryonic kidney) cells used
in this study were obtained from the European Collection of
Animal and Cell Cultures (Salisbury, UK) and maintained in
Dulbecco’s modified Eagle’s medium (DMEM) (Life Technolo-
gies) supplemented with 10% fetal calf serum (FCS) (PAA Lab-
oratories or Sigma) at 37 °C in 5% CO2. Bone marrow-derived
macrophages (BMDM) were infected with the v-myc/v-raf
expressing J2 retrovirus (30) and differentiated in 20% LCM
(L929 cell (ATCC) conditioned medium). Cells were then
maintained in DMEM (Sigma), 10% FCS, 20% LCM, and 1 mM
sodium pyruvate at 37 °C, 5% CO2.
Crystallization and Structure Determination—SpvD4CS and
SpvD4CS/C73A/G161 proteins at 9 mg/ml in 50 mM Tris/Cl, pH
7.5, 50 mM NaCl, and 10 mM -mercaptoethanol were crystal-
lized by vapor diffusion in hanging drops against a reservoir of
100 mM Tris/Cl, pH 7.5, 200 mM NaCl, 22% PEG3350 at 4 °C.
Two different crystal morphologies grew in the drops, and
seeding was used to propagate the three-dimensional crystal
form, which diffracted consistently to high resolution. SpvD4CS
crystals were transferred to a cryoprotectant solution of 100
mM Tris/Cl, pH 7.5, 200 mM NaCl, 22% PEG3350, and 20%
glycerol and flash-frozen in liquid nitrogen, and diffraction data
were collected to 1.48 Å on beamline I03 at Diamond Light
Source (Oxfordshire, UK) (Table 1). Anomalous data were col-
lected on I04-1 at Diamond Light Source from a crystal soaked
for 1 h in 100mMTris/Cl, pH 7.5, 200mMNaCl, 22% PEG3350,
20% glycerol, 1 mM KAuCl4. SpvD4CS/C73A/G161 crystals were
grown as above and transferred stepwise with increasing con-
centrations of dimethyl sulfoxide (DMSO) and Z-RLRGG-ami-
noluciferin (Promega) to a final solution of 100mMTris/Cl, pH
7.5, 200mMNaCl, 22%PEG3350, 25%DMSO, 1mMZ-RLRGG-
aminoluciferin before flash-freezing and collecting data at Dia-
mond Light Source beamline I02. Native data were integrated
inMosflm (31) andmerged in Scala (32) of the CCP4 suite (33),
and anomalous data were processed with the xia2 pipeline
using XDS and XSCALE (34–37). The structure was solved by
single isomorphous replacement with anomalous scattering in
Phenix using the AutoSol wizard (38, 39) with one site and an
initial figure of merit of 0.35. The initial structure was built by
Phenix AutoBuild wizard (40) and refined using Refmac and
Phenix (38, 41) iterated with manual model building in Coot
(42). Structures were refined to final resolutions of 1.48 Å (Arg-
161) and 1.60 Å (Gly-161) with good geometry (Table 1).
The coordinates and structure factors of the structures of
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SpvD4CS/R161 and SpvD4CS/C73A/G161 have been deposited in the
protein data bank with PDB codes 5LQ6 and 5LQ7, respectively.
DNA Transfection—HEK293 cells were seeded in 24-well
plates at a concentration of 2 104 cells/well 24 h before trans-
fection with Lipofectamine 2000 (Life Technologies) following
the manufacturer’s protocol. Cells were used 24 h after
transfection.
Fixation, Permeabilization, Fluorescence Labeling, andMicros-
copy—All sampleswere fixed in 3%paraformaldehyde. Permea-
bilization was done in 0.2% Triton X-100 together with incuba-
tion with primary antibodies. All antibodies were diluted to the
appropriate concentrations in PBS containing 10%horse serum
and 0.2% Triton-X100. The coverslips were washed once in
PBS, incubated with primary antibodies for 2 h, washed 3 times
in PBS, and incubated with secondary antibodies and nucleic
acid dyeDAPI (Thermo Fisher) for 1 h. Coverslips were washed
and mounted onto glass slides using Mowiol mounting
medium. Cells were analyzed using a confocal laser-scanning
microscope (LSM710; Zeiss GmbH).
Luciferase Reporter Assay—HEK293 cells were seeded at a
density of 5  104 cells per well in a 24-well plate 24 h before
transfection. Cells were transfected for 24 h with 50 ng of lucif-
erase reporter plasmid (NF-B dependent luciferase reporter
plasmid), 30 ng of pTK-Renilla luciferase, and 500 ng of expres-
sion vectors (SpvD, SseK3, IBS32A/S36A or pRK5 vector
alone). Cells were then incubated eitherwith 10 ng/ml TNF or
100 nM PMA for 16 h and harvested in 100 l of passive lysis
buffer (Promega). Luciferase activity was measured using the
Dual Luciferase reporter assay system (Promega) and Infinite
M200Pro plate reader (Tecan) and normalized according to
Renilla luciferase intensity. The data presented are from at least
four independent experiments.
Mice Infections—To prepare the inocula, bacteria were first
grown overnight in LB broth and then subcultured at a dilution
of 1:100 for a further 2 h. Cultures were diluted to a concentra-
tion of 5 103 cfu/ml in physiological saline. For CI measure-
ments, bacterial cultures were mixed for intraperitoneal inoc-
ulation (0.2 ml per mouse). Viable bacteria in inocula were
quantified by dilution and plating onto LB agar plates with
appropriate antibiotics to distinguish between strains. Female
C57BL/6 mice (Charles River, 6–8 weeks) were sacrificed at 3
days post inoculation. The spleens were removed aseptically
and homogenized in distilled water by mechanical disruption.
Serial dilutions were plated on LB agar for cfu enumeration.
Strains were distinguished by differential counting or replica
plating on antibiotic-supplemented plates. For eachmouse, the
CIwas calculated by dividing the output ratio (i.e. strain a versus
strain b) divided by the input ratio. The log CI values were used
to calculate means and for statistical analyses.
Ethics Statement—Animalswere used in accordancewithUK
Home Office regulations. The Imperial College Animal Wel-
fare and Ethical Review Body (AWERB) committee approved
the project license for animal research (70/7768). The following
people formed the panel: Applicant Scientist, CBS site manager/
NACWO, NVS, peer scientist, and a lay person.
Statistical Analysis—All results are reported as the mean 
S.E. Statistical analyses were done using one-tailed paired
Student’s t test or ANOVA followed by Bonferroni’s multiple
comparison test. Differences denoted in the text as significant
represent p values lower than 0.05.
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